IRVING, Texas, June 22, 2010 (GLOBE NEWSWIRE) -- Caris Life Sciences(TM), a leading biosciences company focused on driving precise and personalized healthcare, today announced that it has named Dominic P. Moorhead as President of European operations. This appointment and the expansion into Europe underline the growing demand for novel diagnostic, prognostic and theranostic testing services. European operations will play a pivotal role in the development and commercialization of the company’s promising Carisome(TM) platform -- a proprietary blood-based technology currently being developed for earlier, more accurate and less invasive testing for cancer and other complex diseases. In addition the new organization will drive the commercialization of the innovative Caris Target Now(R) molecular profiling and therapeutic guidance test in Europe.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7644
As Caris’ President of European operations, Moorhead will be responsible for rapidly establishing and building-up the company’s European operations. Plans include a European headquarters, initially located in Lausanne, Switzerland, and a laboratory network across Europe, supporting partnerships with prominent research institutions, universities and hospitals that share Caris’ goal of bringing personalized healthcare to patients.
Moorhead joins Caris with 26 years of finance and operations management expertise in the European healthcare sector. In particular, for the past nine years, he has served as Chief Financial Officer for Roche Pharmaceuticals, where he was involved in all aspects of business leadership as a member of the Pharma Executive Committee. He has deep experience in leading a global finance organization and dealing with the challenges of driving and nurturing a dynamic business in a global environment. He earned a BSc Honours Degree in Chemistry at the University of Nottingham, and is qualified as a Fellow of the Institute of Chartered Accountants in England & Wales (FCA).
“Europe is the natural next step in Caris’ expansion as we work to reduce the global impact of complex diseases like cancer, through earlier and more accurate diagnosis and therapeutic guidance,” said Chairman and CEO, David D. Halbert. “We are pleased to have Dominic on the team to lead our efforts in helping the European health systems deliver truly personalized medicine to their patients through the use of innovative, cost-effective and highly-accurate testing services.”
“I am excited to be part of the expanding Caris leadership team as the company grows its global presence and becomes an even greater force in making personalized healthcare a reality,” Moorhead said. “We are looking forward to significant collaborations and partnerships throughout the region, in order to rapidly advance Caris’ new proprietary platforms for diagnosis, prognosis and therapeutic guidance for cancer and other complex diseases.”
About Caris Life Sciences
Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing the Carisome(TM) platform, a proprietary, blood-based technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, and operates laboratories at the headquarters, as well as in the Phoenix and Boston metro areas. For more information, visit www.carislifesciences.com.
The photo is also available via AP PhotoExpress.
CONTACT: Caris Life Sciences Media Inquiries: Holly Clark 214-596-7060 hclark@carisls.com
